Literature DB >> 16309500

Multiple cutaneous and uterine leiomyomata resulting from missense mutations in the fumarate hydratase gene.

G S Chuang1, A Martinez-Mir, D E Engler, R F Gmyrek, A Zlotogorski, A M Christiano.   

Abstract

Multiple cutaneous and uterine leiomyomata (MCL) is an autosomal dominant disorder characterized by the development of benign smooth muscle tumours (leiomyomas) in the skin and uterus of affected women, and in the skin of affected men. In rare cases, MCL has been associated with a predisposition to the rare type II papillary renal cell cancer, also known as hereditary leiomyomatosis and renal cell cancer. The genetic locus for MCL has been mapped to chromosome 1q42.3-43 and subsequently, germline mutations in the fumarate hydratase (FH) gene have been identified. In addition, analysis of FH in some tumours of MCL patients revealed a second mutation inactivating the wild-type allele, suggesting that FH may function as a tumour suppressor gene. Here, we report two cases of MCL patients with FH mutations, designated as T287P and R190L. T287P represents a novel mutation of a highly conserved amino acid of the FH protein. In addition, a patient with an unusual clinical presentation of MCL was found to have the recurrent mutation, R190L, raising the possibility of incorporating FH sequencing as a diagnostic tool. Our findings extend the allelic series of mutations in FH and support its status as the underlying cause of MCL.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16309500     DOI: 10.1111/j.1365-2230.2005.01977.x

Source DB:  PubMed          Journal:  Clin Exp Dermatol        ISSN: 0307-6938            Impact factor:   3.470


  8 in total

1.  Familial renal cancer as an indicator of hereditary leiomyomatosis and renal cell cancer syndrome.

Authors:  Victoria M Raymond; Casey M Herron; Thomas J Giordano; Stephen B Gruber
Journal:  Fam Cancer       Date:  2012-03       Impact factor: 2.375

2.  No evidence for a genetic modifier for renal cell cancer risk in HLRCC syndrome.

Authors:  Pia Vahteristo; Taru A Koski; Laura Näätsaari; Maija Kiuru; Auli Karhu; Riitta Herva; Satu-Leena Sallinen; Outi Vierimaa; Erik Björck; Stéphane Richard; Betty Gardie; Didier Bessis; Emmanuel Van Glabeke; Ignacio Blanco; Richard Houlston; Leigha Senter; Marja Hietala; Kristiina Aittomäki; Lauri A Aaltonen; Virpi Launonen; Rainer Lehtonen
Journal:  Fam Cancer       Date:  2010-06       Impact factor: 2.375

Review 3.  Hereditary leiomyomatosis and renal cell cancer (HLRCC): renal cancer risk, surveillance and treatment.

Authors:  Fred H Menko; Eamonn R Maher; Laura S Schmidt; Lindsay A Middelton; Kristiina Aittomäki; Ian Tomlinson; Stéphane Richard; W Marston Linehan
Journal:  Fam Cancer       Date:  2014-12       Impact factor: 2.375

Review 4.  Inherited skin tumour syndromes.

Authors:  Sarah Brown; Paul Brennan; Neil Rajan
Journal:  Clin Med (Lond)       Date:  2017-12       Impact factor: 2.659

5.  Multiple cutaneous and uterine leiomyomatosis syndrome: a review.

Authors:  Sonal Choudhary; Michael McLeod; Daniele Torchia; Paolo Romanelli
Journal:  J Clin Aesthet Dermatol       Date:  2013-04

6.  Hereditary leiomyomatosis and renal cell cancer: update on clinical and molecular characteristics.

Authors:  Heli J Lehtonen
Journal:  Fam Cancer       Date:  2011-06       Impact factor: 2.446

7.  Hereditary leiomyomatosis and renal cell cancer presenting as metastatic kidney cancer at 18 years of age: implications for surveillance.

Authors:  Karin Y van Spaendonck-Zwarts; Sadhanna Badeloe; Sjoukje F Oosting; Sjoerd Hovenga; Harry J F Semmelink; R Jeroen A van Moorselaar; Jan Hein van Waesberghe; Arjen R Mensenkamp; Fred H Menko
Journal:  Fam Cancer       Date:  2012-03       Impact factor: 2.375

8.  Uterine smooth muscle tumors with features suggesting fumarate hydratase aberration: detailed morphologic analysis and correlation with S-(2-succino)-cysteine immunohistochemistry.

Authors:  Carolina Reyes; Yevgeniy Karamurzin; Norma Frizzell; Karuna Garg; Daisuke Nonaka; Ying-Bei Chen; Robert A Soslow
Journal:  Mod Pathol       Date:  2013-12-06       Impact factor: 7.842

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.